Visby Medical is a private diagnostics company focused on rapid PCR platforms, and this weekly summary highlights its latest initiatives in women’s and sexual health. The company continued to promote its FDA-authorized at-home PCR STI test for women, which provides lab-quality results for chlamydia, gonorrhea, and trichomoniasis in about 30 minutes without a clinic visit.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Visby advanced its Safe Access Program with RAINN, the nation’s largest anti-sexual violence organization, to support sexual-assault survivors through private at-home STI testing. The initial rollout will distribute 1,000 test kits across 20 RAINN partner programs, with an emphasis on rural and underserved communities that face barriers to sexual-health services.
Participants who test positive through the program can connect with a third-party licensed telehealth provider for a complimentary consultation and, when appropriate, a prescription, creating an integrated care pathway. While still pilot-scale, this structure could later support broader deployment with health systems, NGOs, or public-sector buyers if demand and partnerships expand.
The company also highlighted a partnership with telehealth provider Wisp to launch an at-home PCR STI test targeted specifically to women, integrating rapid diagnostics with virtual care and aiming to reduce delays and missed follow-ups. In parallel, engagement with retail lab franchise Any Lab Test Now signals potential expansion into community-based testing sites and further diversification of distribution channels.
A recent Women’s Health Week panel appearance by CEO Adam de la Zerda reinforced Visby Medical’s emphasis on access-focused growth and responsible scaling in women’s health. The company is positioning its rapid, lab-grade technology for deployment through nontraditional channels and advocacy partners such as RAINN and DoorDash, with use cases spanning survivor support, at-home care, and expanded delivery access.
Involvement with brands like Uber Health and Progyny, Inc. underscores alignment with established digital health and benefits platforms, which may offer additional routes to market if relationships deepen beyond thought leadership. Collectively, the focus on decentralized testing, telehealth integration, and partnerships could broaden Visby Medical’s addressable market, though execution will depend on successfully managing regulatory, payer, and operational challenges.
These developments indicate steady momentum in commercialization and distribution for Visby Medical’s women’s health and STI testing offerings. Overall, the week underscored a strategic push toward scalable, access-oriented models that aim to embed Visby’s rapid diagnostics across advocacy networks, virtual care ecosystems, and community settings.